SLRX
Income statement / Annual
Last year (2024), Salarius Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Salarius Pharmaceuticals, Inc.'s net income was -$5.58 M.
See Salarius Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$1.84 M |
$5.23 M |
$3.47 M |
$838,142.00 |
$1.27 M |
$1.01 M |
$0.00 |
| Cost of Revenue |
$0.00
|
$10,051.00
|
$6,677.00
|
$19,183.00
|
$6,913.85
|
$4,018.95
|
$430,750.00
|
$506,530.00
|
$662,747.00
|
$49,881.00
|
| Gross Profit |
$0.00
|
-$10,051.00
|
-$6,677.00
|
$1.82 M
|
$5.23 M
|
$3.46 M
|
$407,392.00
|
$767,969.00
|
$347,916.00
|
-$49,881.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0.99
|
1
|
1
|
0.49
|
0.6
|
0.34
|
0
|
| Research and Development Expenses |
$770,027.00
|
$7,173.75
|
$15.84 M
|
$8.55 M
|
$6.91 M
|
$4.02 M
|
$11.91 M
|
$16.99 M
|
$20.38 M
|
$12.75 M
|
| General & Administrative Expenses |
$4.96 M
|
$5,721.20
|
$7.14 M
|
$6.10 M
|
$6.11 M
|
$7.71 M
|
$2.35 M
|
$1.37 M
|
$797,485.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$8.22 M
|
$17.14 M
|
$19.06 M
|
$0.00
|
| Selling, General & Administrative Expenses |
$4.96 M
|
$5,721.20
|
$7.14 M
|
$6.10 M
|
$6.11 M
|
$7.71 M
|
$10.57 M
|
$18.50 M
|
$19.86 M
|
$16.46 M
|
| Other Expenses |
$0.00
|
$0.00
|
-$0.00
|
-$4.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$5.73 M
|
$12,894.00
|
$22.98 M
|
$14.65 M
|
$13.02 M
|
$11.73 M
|
$22.48 M
|
$35.49 M
|
$40.23 M
|
$29.21 M
|
| Cost And Expenses |
$0.00
|
$22,945.00
|
$22.98 M
|
$14.65 M
|
$13.02 M
|
$11.73 M
|
$22.91 M
|
$36.00 M
|
$40.90 M
|
$29.21 M
|
| Interest Income |
$158,539.00
|
$352,251.00
|
$218.73
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$3,047.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$10,051.00
|
$6,677.00
|
$19,183.00
|
$18,058.00
|
$127,408.00
|
$0.00
|
$324,548.00
|
$277,231.00
|
$49,881.00
|
| EBITDA |
-$5.57 M |
-$2,843.94 |
-$31.60 M |
-$12.79 M |
-$7.33 M |
-$8.14 M |
-$22.07 M |
-$34.11 M |
-$39.22 M |
-$29.09 M |
| EBITDA Ratio |
0
|
0
|
0
|
-6.95
|
-1.4
|
-2.35
|
-26.34
|
-26.76
|
-38.8
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
-6.96
|
-1.49
|
-2.39
|
-26.34
|
-27.25
|
-39.47
|
0
|
| Total Other Income/Expenses Net |
$158,539.00
|
-$12.53 M
|
$233,184.00
|
$44,697.00
|
$434,091.00
|
$1.33 M
|
$152,006.00
|
$291,964.00
|
$393,109.00
|
$72,000.00
|
| Income Before Tax |
-$5.58 M
|
-$12.54 M
|
-$31.61 M
|
-$12.77 M
|
-$7.35 M
|
-$6.94 M
|
-$21.92 M
|
-$34.43 M
|
-$39.49 M
|
-$29.14 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
-6.94
|
-1.4
|
-2
|
-26.16
|
-27.02
|
-39.08
|
0
|
| Income Tax Expense |
$0.00
|
-$12.53 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$630.00
|
| Net Income |
-$5.58 M
|
-$12.54 M
|
-$31.37 M
|
-$12.77 M
|
-$7.35 M
|
-$6.94 M
|
-$21.92 M
|
-$34.43 M
|
-$39.49 M
|
-$29.14 M
|
| Net Income Ratio |
0
|
0
|
0
|
-6.94
|
-1.4
|
-2
|
-26.16
|
-27.02
|
-39.08
|
0
|
| EPS |
-5.79 |
-0.0038 |
-14.77 |
-62 |
-100 |
-424 |
-6100 |
-9950 |
-12150 |
-1297.92 |
| EPS Diluted |
-5.79 |
-0.0038 |
-14.77 |
-62 |
-100 |
-424 |
-6100 |
-9950 |
-12150 |
-1297.92 |
| Weighted Average Shares Out |
$962,210.00
|
$3.26 M
|
$2.12 M
|
$206,000.00
|
$77,893.00
|
$16,343.00
|
$18.02 M
|
$17.26 M
|
$16.23 M
|
$22,452.00
|
| Weighted Average Shares Out Diluted |
$962,210.00
|
$3.26 M
|
$2.12 M
|
$206,829.00
|
$77,893.00
|
$16,343.00
|
$18.02 M
|
$17.26 M
|
$16.23 M
|
$22,452.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
